Strategic Communications and Marketing News Bureau

Surgical probe seeks out where cancer ends and healthy tissue begins

CHAMPAIGN, Ill. – A new surgical tool that uses light to make sure surgeons removing cancerous tumors “got it all” was found to correlate well with traditional pathologists’ diagnoses in a clinical study, showing that the tool could soon enable reliable, real-time guidance for surgeons.

The interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois. The results appear in the journal Cancer Research.

One difficult but crucial determination for surgeons and tissue pathologists is figuring out where a tumor ends. A solid tumor may be easily identifiable, but the tissue around the main body of the tumor, known as the margin, may contain cancerous cells as well. Because of this, excess tissue surrounding the tumor is typically removed, but the question lingers of whether any cancer cells remain to re-emerge later as tumors.

“In almost all solid-tumor surgeries, there’s a question of margins,” said Dr. Boppart, who also is a medical doctor. “Typically, surgeons will remove the tissue mass that contains the tumor and will send it to the lab. The pathologist will process, section and stain the tissue, then examine the thin sections on microscope slides. They look at the structure of the cells and other features of the tissue. The diagnosis is made based on subjective interpretation and often other pathologists are consulted. This is what we call the gold standard for diagnosis.”

The new device is a hand-held probe based on a technology called optical coherence tomography (OCT) that uses light to image tissue in real time. Cancer cells and normal tissue scatter light differently because they have different microstructural and molecular features, Boppart said, so OCT gives physicians a way to quantitatively measure the cellular feature of a tumor. Surgeons can pass the OCT wand over a section of tissue and see a video on a screen, with no special chemical stains or lengthy tissue processing required.

“In many cases, you can’t tell the difference between cancer cells and normal tissue with the naked eye, but with OCT they’re very different,” said Boppart, who also is affiliated with the Beckman Institute for Advanced Science and Technology at the U. of I.

In the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later. The study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity. They also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.

“For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,” Boppart said. “It is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out. Then, the surgeon can intervene immediately.”

The researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors. Diagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.

“Ultimately, new technological innovations like this in medicine and surgery are going to improve our health care and save lives. That’s when this work will be most rewarding,” Boppart said.

The National Institutes of Health supported this work.

Editor’s notes: Editor’s note: To reach Stephen Boppart, call 217-244-7479; email: boppart@illinois.edu.

The paper “Real-time imaging of the resection bed using a handheld probe to reduce incidence of microscopic positive margins in cancer surgery” is available online.

Read Next

Health and medicine Dr. Timothy Fan, left, sits in a consulting room with the pet owner. Between them stands the dog, who is looking off toward Fan.

How are veterinarians advancing cancer research in dogs, people?

CHAMPAIGN, Ill. — People are beginning to realize that dogs share a lot more with humans than just their homes and habits. Some spontaneously occurring cancers in dogs are genetically very similar to those in people and respond to treatment in similar ways. This means inventive new treatments in dogs, when effective, may also be […]

Honors From left, individuals awarded the 2025 Campus Awards for Excellence in Public Engagement are Antoinette Burton, director of the Humanities Research Institute; Ariana Mizan, undergraduate student in strategy, innovation and entrepreneurship; Lee Ragsdale, the reentry resource program director for the Education Justice Project; and Ananya Yammanuru, a graduate student in computer science. Photos provided.

Awards recognize excellence in public engagement

The 2025 Campus Awards for Excellence in Public Engagement were recently awarded to faculty, staff and community members who address critical societal issues.

Uncategorized Portrait of the researchers standing outside in front of a grove of trees.

Study links influenza A viral infection to microbiome, brain gene expression changes

CHAMPAIGN, Ill. — In a study of newborn piglets, infection with influenza A was associated with disruptions in the piglets’ nasal and gut microbiomes and with potentially detrimental changes in gene activity in the hippocampus, a brain structure that plays a central role in learning and memory. Maternal vaccination against the virus during pregnancy appeared […]

Strategic Communications and Marketing News Bureau

507 E. Green St
MC-426
Champaign, IL 61820

Email: stratcom@illinois.edu

Phone (217) 333-5010